CLEVELAND — Researchers at University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine announced today they are accepting volunteers into a clinical trial of an experimental treatment aimed at improving memory and thinking in patients with Alzheimer’s disease.
The compound, ABT-089, is being developed by Abbott. It is designed to activate receptors on nerve cells in the brain that regulate the release of neurotransmitters, chemicals that nerve cells use to communicate with one another. In patients with Alzheimer’s disease, these nerve cells lose the ability to communicate with one another and eventually they die.
“This is an interesting new concept in the treatment of Alzheimer’s disease,” stated Dr. Alan Lerner, the Principal Investigator of the study and Director of the Memory and Cognition Center of the Neurological Institute at UHCMC.